Article Text

Download PDFPDF
Severe bradycardia associated with crizotinib
  1. Ko Kwan Lung,
  2. Calvin Liu,
  3. Bernard Cheung
  1. Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
  1. Correspondence to Professor Bernard Cheung, Department of Medicine, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, Hong Kong; mycheung{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Crizotinib is a multitarget tyrosine kinase inhibitor used in treating non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene mutation. Common and well-known adverse effects include gastrointestinal disturbance, dizziness, fatigue, liver enzyme elevation and visual disturbance. We describe here a patient with NSCLC who presented with symptomatic bradycardia due to crizotinib.

The patient was a 69-year-old Chinese male with stage IV epidermal growth factor receptor-negative, ALK-rearranged NSCLC. He presented to the emergency department complaining of breathlessness, swollen legs and hiccups. He had type 2 diabetes mellitus but no previous cardiovascular disease. He was taking crizotinib 250 mg twice daily, vildagliptin …

View Full Text


  • Contributors KKL is responsible for writing the manuscript. CL is responsible for obtaining patient consent and summarising patient’s clinical record. BC is responsible for supervising and providing advice on patient management and drafting of the manuscript.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.